Dyslipidemia Stocks List

Dyslipidemia Stocks Recent News

Date Stock Title
May 8 MDGL Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript
May 8 ARGX Argenx SE Q1 2024 Earnings Preview
May 8 IONS Ionis Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
May 8 ABT Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
May 8 ABT The Zacks Analyst Blog Highlights Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips
May 8 IONS Q1 2024 Ionis Pharmaceuticals Inc Earnings Call
May 8 IONS Ionis Pharmaceuticals Inc (IONS) Q1 2024 Earnings Call Transcript Highlights: Key Developments ...
May 8 MDGL Madrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
May 7 IONS Ionis Pharmaceuticals, Inc. (IONS) Q1 2024 Earnings Call Transcript
May 7 ARGX argenx announces results of Annual General Meeting of Shareholders
May 7 ABT 13 Best Stocks That Will Always Grow
May 7 MDGL Madrigal Pharmaceuticals (MDGL) Q1 2024 Earnings Call Transcript
May 7 MDGL Madrigal sees ‘tremendous interest’ in new NASH drug Rezdiffra
May 7 IONS Ionis Pharmaceuticals (IONS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
May 7 MDGL Madrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra Launch
May 7 IONS Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates
May 7 IONS Ionis Pharmaceuticals GAAP EPS of -$0.98 beats by $0.09, revenue of $119M misses by $17.41M
May 7 MDGL Madrigal Pharmaceuticals GAAP EPS of -$7.38 misses by $1.18
May 7 MDGL Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
May 7 IONS Ionis reports first quarter 2024 financial results
Dyslipidemia

Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle. Prolonged elevation of insulin levels can also lead to dyslipidemia. Likewise, increased levels of O-GlcNAc transferase (OGT) may cause dyslipidemia.

Browse All Tags